BR9814419A - "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" - Google Patents

"combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"

Info

Publication number
BR9814419A
BR9814419A BR9814419-7A BR9814419A BR9814419A BR 9814419 A BR9814419 A BR 9814419A BR 9814419 A BR9814419 A BR 9814419A BR 9814419 A BR9814419 A BR 9814419A
Authority
BR
Brazil
Prior art keywords
proliferative diseases
combination
antineoplastic drugs
treatment
compounds
Prior art date
Application number
BR9814419-7A
Other languages
English (en)
Inventor
Walter R Bishop
Joseph J Catino
Ronald J Doll
Ashit Ganguly
Viyyoor Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L Nielsen
David L Cutler
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814419(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9814419A publication Critical patent/BR9814419A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE COMPOSTOS DE BENZOCICLO-HEPTAPIRIDINA E DROGAS ANTINEOPLáSTICAS PARA TRATAMENTO DE DOENçAS PROLIFERATIVAS"<D>. Métodos são providos para tratamento de doenças proliferativas, especialmente cânceres, compreendendo a administração de (1) um inibidor de trasferase de proteína farnesila em conjunto com (2) um agente ntineoplástico e/ou terapia de radiação.
BR9814419-7A 1997-12-22 1998-12-21 "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" BR9814419A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (1)

Publication Number Publication Date
BR9814419A true BR9814419A (pt) 2000-10-10

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814419-7A BR9814419A (pt) 1997-12-22 1998-12-21 "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"

Country Status (25)

Country Link
EP (1) EP1041985B1 (pt)
JP (1) JP4502503B2 (pt)
KR (1) KR100700907B1 (pt)
CN (1) CN1129431C (pt)
AR (1) AR017440A1 (pt)
AT (1) ATE317697T1 (pt)
AU (1) AU756762B2 (pt)
BR (1) BR9814419A (pt)
CA (1) CA2315693C (pt)
CL (1) CL2007001889A1 (pt)
CO (1) CO5080764A1 (pt)
CZ (1) CZ298511B6 (pt)
DE (1) DE69833509T2 (pt)
DK (1) DK1041985T3 (pt)
ES (1) ES2255196T3 (pt)
HU (1) HUP0102473A3 (pt)
IL (1) IL136462A0 (pt)
MY (1) MY137303A (pt)
NO (1) NO326832B1 (pt)
NZ (1) NZ504928A (pt)
PE (1) PE20000042A1 (pt)
PT (1) PT1041985E (pt)
SK (1) SK285584B6 (pt)
TW (1) TW581763B (pt)
WO (1) WO1999032114A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
AU1400401A (en) * 1999-11-09 2001-06-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale
CZ292791B6 (cs) * 1995-12-22 2003-12-17 Schering Corporation Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000508661A (ja) * 1996-04-15 2000-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 放射線および化学療法に対する細胞の感作
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
HUP0004326A3 (en) * 1997-02-18 2003-07-28 Canji Inc San Diego Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
MY137303A (en) 2009-01-30
KR100700907B1 (ko) 2007-03-29
TW581763B (en) 2004-04-01
NO20003229L (no) 2000-08-22
CO5080764A1 (es) 2001-09-25
DK1041985T3 (da) 2006-06-19
WO1999032114A1 (en) 1999-07-01
AR017440A1 (es) 2001-09-05
CA2315693A1 (en) 1999-07-01
EP1041985B1 (en) 2006-02-15
DE69833509D1 (de) 2006-04-20
PE20000042A1 (es) 2000-02-17
NO20003229D0 (no) 2000-06-21
CN1284875A (zh) 2001-02-21
CZ298511B6 (cs) 2007-10-24
JP4502503B2 (ja) 2010-07-14
JP2001526224A (ja) 2001-12-18
IL136462A0 (en) 2001-06-14
AU1907299A (en) 1999-07-12
DE69833509T2 (de) 2006-10-26
CA2315693C (en) 2010-11-30
CL2007001889A1 (es) 2008-01-11
NZ504928A (en) 2004-12-24
SK285584B6 (sk) 2007-04-05
AU756762B2 (en) 2003-01-23
ATE317697T1 (de) 2006-03-15
CN1129431C (zh) 2003-12-03
NO326832B1 (no) 2009-02-23
PT1041985E (pt) 2006-07-31
HUP0102473A2 (hu) 2002-01-28
CZ20002236A3 (cs) 2001-04-11
KR20010033452A (ko) 2001-04-25
EP1041985A1 (en) 2000-10-11
ES2255196T3 (es) 2006-06-16
HUP0102473A3 (en) 2003-07-28
SK8982000A3 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
NO964527D0 (no) Blandinger omfattende DNA-ödeleggende midler og P53
BG105108A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer&#39;s disease
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2&#39;-halometilideno y un agente antineoplasico especifico de fase s o fase m.
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
ATE241993T1 (de) Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
MD798G2 (ro) Metoda de tratament a cancerului mamar
ATE233745T1 (de) Arzneistoffe
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
BR9708037A (pt) Método para o tratamento de abuso de substância
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
BR9810930A (pt) Composições farmacêuticas de arglabina e derivados de arglabina
PT872238E (pt) Utilizacao de olanzapina para o fabrico de um medicamento para neuroproteccao

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.